Immutep Ltd · ASX:IMM
Immutep — Investor Presentation (May 2018)
37 slides from Immutep's investor presentation, May 2018
Slide 1: The global leader in developing LAG-3 therapeutics
The global leader in developing LAG-3 therapeutics Investor Presentation May 2018 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cla
Slide 3: Investment Highlights
Investment Highlights The global leader in Broadest LAG-3 portfolio developing LAG-3 Deep expertise and with four product candidates, therapeutics for IP in the LAG-3 immune three of which are in eight immuno-oncology and control mechanism ongoing clinical trials autoimmune diseases Expecting clinic
Slide 4: Company Snapshot
Company Snapshot Capital Structure • Globally active biotechnology company with IMM (Australian Securities Exchange) operations in Australia, Europe and U.S. Ticker symbols IMMP (NASDAQ - ADRs) • Four LAG-3 related product candidates in Securities on issue 3.0 billion ordinary shares development in
Slide 5: Recent Achievements
Recent Achievements BROADEN PARTNERSHIPS SECURE FURTHER FUNDING • Merck collaboration signed March 2018 • AUD13.16m Placement and SPP in April 2018 • Ongoing partnerships with GSK, Novartis and • ~US$2m in milestone payments from EOC / Eddingpharm Eddingpharm and Novartis • Active Business Developme
Slide 6: LAG-3 Overview & Product Candidates
LAG-3 Overview & Product Candidates 6
Slide 7: LAG-3 as a Therapeutic Target
LAG-3 as a Therapeutic Target • LAG-3 is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells → Prime target for an immune checkpoint blocker • Functionally similar to CTLA-4 (targeted by Yervoy®) and PD-1 (targeted by Keytruda®) • There are currently no approved therapeut
Slide 8: Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications
Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications IMMUNOSTIMULATION IMMUNOSUPPRESSION IMP321 APC Activator APC Agonistic mAb IMP761 MHCII Depleting LAG-3 mAb Antagonistic Partnered with mAb Partnered with LAG-3 T-Cell T-Cell Rheumatoid IBD Multiple Sclerosis Immuno-oncology V
Slide 9: Oncology and Autoimmune Pipeline
Oncology and Autoimmune Pipeline* Eftilagimod Alpha (LAG-3Ig or IMP321), APC Activator – Fusion Protein Preclinical Phase I Phase IIa Phase IIb Commercial Rights/ Partners Chemo-Immuno Combo (MBC) 2019(1) Immutep Global Rights IO-IO Combination(2) (Chinese rights: (Solid Tumors) 2018/2019(1) Eddingp
Slide 10: Lead Program Eftilagimod Alpha (IMP321)
Lead Program Eftilagimod Alpha (IMP321) 10
Slide 11: Existing Immuno-Oncology Landscape
Existing Immuno-Oncology Landscape Current Immuno-Oncology Therapies Evolution of Immuno-Oncology Therapies • Existing immuno-oncology therapies are Opdivo/ anti-LAG-3 CTLA-4, PD-1 and PD-L1 antagonists and are Opdivo/ Yervoy Combination* approved for many disease indications combination • However,
Slide 12: IO Therapy Oncology Response Rates
IO Therapy Oncology Response Rates Approximately 70-80% of patients do no respond to anti-PD1 monotherapy How can we enable more efficacious T-cell responses? • Immunogenic cell death to liberate/uncover tumor antigens • Cross-presentation of those antigens • Recruitment of T cells into the tumor mi
Slide 13: Eftilagimod Alpha: Innovative LAG-3 IO Product Candidate
Eftilagimod Alpha: Innovative LAG-3 IO Product Candidate • The only APC targeting LAG-3 product currently in clinical development • A unique approach (“turning cold tumors into hot tumors” with LAG-3) • Synergistic with other I-O agents “PUSHING THE ACCELERATOR ON IMMUNE RESPONSES” “RELEASING THE BR
Slide 14: Opportunity for Eftilagimod Alpha
Opportunity for Eftilagimod Alpha Eftilagimod has the potential to be an ideal combination candidate in oncology therapy that could improve the prognosis for patients Eftilagimod Key Characteristics (based on current data): • Excellent safety profile and encouraging efficacy data thus far • Potentia
Slide 15: Eftilagimod Alpha in MBC (AIPAC)
Eftilagimod Alpha in MBC (AIPAC) (chemo-immunotherapy) AIPAC trial (Phase IIb): Active Immunotherapy PAClitaxel, MBC patients, different EU countries Arm 1, 113 patients: Phase IIb, Safety-run in, paclitaxel + IMP321 Run-in: recommended multinational, 15 (6+9) patients, Stage 2 Phase II dose (RP2D)
Slide 16: Eftilagimod Alpha Prelim. Efficacy Metastatic Breast Cancer
Eftilagimod Alpha Prelim. Efficacy Metastatic Breast Cancer Observed response rates are substantially better than the 22-33% response rates seen in historical control groups with paclitaxel monotherapy Phase I (n=30) AIPAC – Safety Run Phase (n=15) Response Parameter Paclitaxel + IMP321 (n = 15) Com
Slide 17: Eftilagimod Alpha in Melanoma TACTI-mel (IO combination)
Eftilagimod Alpha in Melanoma TACTI-mel (IO combination) TACTI-mel trial: Two ACTive Immunotherapeutics in melanoma 24 patients, Recommended Phase I, multicenter, Part A: 3 cohorts IMP321 + anti-PD-1 Phase II dose open label, of 6 pts (Keytruda) safety and dose escalation Part B: 6 pts tolerability
Slide 18: TACTI-mel Patient 02-01 (1mg): Preliminary Results
Eftilagimod Alpha TACTI-mel Patient 02-01 (1mg): Preliminary Results Efficacy: metastatic melanoma pre-pembro week 9 (pembro) week 25 (combo) week 37 (combo) R L R L R L R L irPD week 49 (Pembro mono) week 64 (PFS-FU) R L R L All lesions disappeared → CR (confirmed) patient without treatment but dis
Slide 19: TACTI-mel Preliminary Safety and Efficacy Update
Eftilagimod Alpha TACTI-mel Preliminary Safety and Efficacy Update COHORT 1 +2 COHORT 1 +2 T A C T I- m e l w a t eTr fAa C ll TpI-lomt e( ir l RC) A (1 m g ), B (6 m g ) IM P 3 2 1 ir R C a s s e s s m e n ts * % c h a n g e c o m p a re d to s ta r t o f c o m b o 600 w a t e r f a ll p lo t ( ir
Slide 20: Collaboration and Supply Agreement
Collaboration and Supply Agreement • In March 2018 Immutep entered into clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) to evaluate the combination of eftilagimod alpha with MSD's anti-PD-1 therapy KEYT
Slide 21: Eftilagimod Alpha INSIGHT Clinical Trial
Eftilagimod Alpha INSIGHT Clinical Trial Investigator Initiated Trial Eftilagimod Alpha in i.t. and i.p. application • Prof. Al-Batran, IKF, Frankfurt, Germany • Population: 18 patients (9 per stratum) with advanced solid tumors without standard treatment options • Objectives: Recommended Phase II d
Slide 22: Eftilagimod Alpha Partnerships
Eftilagimod Alpha Partnerships • Eddingpharm holds Chinese rights • Chinese IND for IMP321 granted in Dec 2017 -> milestone • EOC, an Eddingpharm spin-off holding the Chinese rights for IMP321, successfully closed $32 Million round for oncology assets in Nov 2017 • Milestone and royalty bearing part
Slide 23: IMP701 (Cancer)
IMP701 (Cancer) LAG-3 IMMUNOTHERAPY
Slide 24: IMP701 for Cancer
IMP701 for Cancer • Novartis holds exclusive WW rights • August 2015: Start of Phase I study of IMP701 in combination with PDR001 (anti-PD- 1 mAb) in 13 different cancer indications in 240 patients • 1st and 2nd Milestone payments received in Aug 2015 and August 2017, respectively • Estimated study
Slide 25: IMP731 (Autoimmune Diseases)
IMP731 (Autoimmune Diseases) 25
Slide 26: IMP731 for Autoimmune Diseases
IMP731 for Autoimmune Diseases • GSK holds exclusive WW rights • Jan 2015: Immutep received a single-digit million US$ milestone payment • Up to ₤64m in total upfront payments and milestones, plus royalties • GSK2831781 in Phase I trials with potential regulatory filing expected within 2021-2025 tim
Slide 27: Market & Competition
LAG-3 IMMUNOTHERAPY Market & Competition
Slide 28: LAG-3 / Autoimmune Diseases
LAG-3 / Autoimmune Diseases The Present Fighting general inflammation: Corticoids, methotrexate, anti-TNF- α,-IL-6 or -IL-17 mAbs The Future Fighting the disease process: Targeting the few autoimmune LAG- 3+ T cells with IMP731 (depleting LAG-3 mAb) or IMP761 (agonist LAG-3 mAb) 28
Slide 29: Significant immuno-oncology market
Significant immuno-oncology market • Immuno-oncology market will 2024 be worth approximately Total: US$34 billion US$14 billion in 2019, rising to US$34 billion by 2024* • Checkpoint inhibitors will account for the bulk of the market share* CHECKPOINT INHIBITORS Source: Immune Checkpoint Inhibitor O
Slide 30: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview Immutep is the leader in developing LAG-3 modulating therapeutics Total Estimated Program Company Preclinical Phase I Phase I/ II Phase II Phase IIb Phase II/III Patients Eftilagimod Alpha Immutep(1), (2) 370 LAG525 Novartis(3), (4) 961 Relatlimab BMS(4), (5) 4,0
Slide 31: Increasing Clinical Trials Targeting LAG-3
Increasing Clinical Trials Targeting LAG-3 Industry increasingly deploying resources to development of LAG-3 therapeutics 35 35 8,000 8,000 30 30 7,000 7,000 30 30 Total Estimated Patients in LAG-3 Trials 6,000 6,000 Number of LAG-3 Clinical Trials Number of LAG-3 Clinical Trials 6,747 6,747 25 25 5
Slide 32: IP & Outlook
: cs) Iimmutep LAG-3 IMMUNOTHERAPY IP & Outlook
Slide 33: Intellectual Property
Intellectual Property Immutep has a strong and continually expanding patent portfolio across major geographic markets and unrivalled expertise and understanding of the LAG-3 immune control mechanism #Plus up to a 5 year extension of term available in some circumstances to compensate for delay associ
Slide 34: Outlook
Outlook Immutep is well funded with a cash runway to calendar Q4 2019, well beyond the final progression free survival data from its Phase IIb AIPAC breast cancer trial. Potential News Flow and Milestones TACTI-mel data from first three cohorts (different doses starting at cycle 5): H1 2018 Clinical
Slide 35: Investment Highlights
Investment Highlights The global leader in Broadest LAG-3 portfolio developing LAG-3 Deep expertise and with four product candidates, therapeutics for IP in the LAG-3 immune three of which are in eight immuno-oncology and control mechanism ongoing clinical trials autoimmune diseases Expecting clinic
Slide 36: Leadership Team
Leadership Team Board Management Russell J Howard, Marc Voigt, Peter A Meyers, Grant Chamberlain, Prof. Frédéric Triebel, Deanne Miller, Non-Executive Chairman Executive Director & CEO Non-Executive Director Non-Executive MD PhD, CSO & CMO, COO, General Counsel and Deputy Chairman Chairman Immutep S
Slide 37: Thank you!
: cs) Iimmutep LAG-3 IMMUNOTHERAPY Thank you!